A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb®13676 (Plamotamab) in Patients with CD20-Expressing Hematologic Malignancies
MD Anderson Study Status
The purpose of this study is to determine the safety and tolerability of intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
For general questions about clinical trials: